Cargando…
2120. Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model
BACKGROUND: Fluconazole is lifesaving for the treatment and prevention of cryptococcosis; however, optimal dosing is unknown. Initial fluconazole doses of 100 mg to 2000 mg/day have been used. Prevalence of fluconazole non-susceptible Cryptococcus is increasing over time, risking the efficacy of lon...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809647/ http://dx.doi.org/10.1093/ofid/ofz360.1800 |
_version_ | 1783462042103971840 |
---|---|
author | Chesdachai, Supavit Rajasingham, Radha Nicol, Melanie R Meya, David Bongomin, Felix Abassi, Mahsa Skipper, Caleb Kwizera, Richard Rhein, Joshua Boulware, David |
author_facet | Chesdachai, Supavit Rajasingham, Radha Nicol, Melanie R Meya, David Bongomin, Felix Abassi, Mahsa Skipper, Caleb Kwizera, Richard Rhein, Joshua Boulware, David |
author_sort | Chesdachai, Supavit |
collection | PubMed |
description | BACKGROUND: Fluconazole is lifesaving for the treatment and prevention of cryptococcosis; however, optimal dosing is unknown. Initial fluconazole doses of 100 mg to 2000 mg/day have been used. Prevalence of fluconazole non-susceptible Cryptococcus is increasing over time, risking the efficacy of long-established standard dosing. Based on current minimum inhibitory concentration (MIC) distribution, we modeled fluconazole concentration and area under the curve (AUC) relative to MIC to propose a rational fluconazole dosing strategy. METHODS: First, we conducted a systematic review using the MEDLINE database for reports of fluconazole MIC distribution against clinical Cryptococcus isolates. Second, we utilized fluconazole concentrations from 92 Ugandans who received fluconazole 800 mg/day coupled with fluconazole’s known pharmacokinetics to predict plasma fluconazole concentrations for doses ranging from 100 mg to 2000 mg via linear regression. Third, the fluconazole AUC above MIC ratio were calculated using Monte Carlo simulation and using the MIC distribution elucidated during the systemic review. RESULTS: We summarized 21 studies with 11,094 clinical Cryptococcus isolates. MICs were normally distributed with geometric mean of 3.4 mg/mL, median (MIC(50)) of 4 mg/mL, and 90th percentile (MIC(90)) of 16 mg/mL. The median MIC(50) trended upwards from 4 mg/mL in 2000–2012 to 8 mg/mL in 2014–2018. Predicted sub-therapeutic fluconazole concentrations (below MIC) would occur in 38% with 100 mg, 20% with 200 mg, and 8% with 400 mg. AUC/MIC ratio > 100 would occur in 53% for 400 mg, 74% for 800 mg, 84% for 1200 mg, and 88% for 1,600 mg. CONCLUSION: Currently recommended fluconazole doses may be inadequate for cryptococcosis. Further clinical studies are needed for rational fluconazole dose selection. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6809647 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-68096472019-10-28 2120. Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model Chesdachai, Supavit Rajasingham, Radha Nicol, Melanie R Meya, David Bongomin, Felix Abassi, Mahsa Skipper, Caleb Kwizera, Richard Rhein, Joshua Boulware, David Open Forum Infect Dis Abstracts BACKGROUND: Fluconazole is lifesaving for the treatment and prevention of cryptococcosis; however, optimal dosing is unknown. Initial fluconazole doses of 100 mg to 2000 mg/day have been used. Prevalence of fluconazole non-susceptible Cryptococcus is increasing over time, risking the efficacy of long-established standard dosing. Based on current minimum inhibitory concentration (MIC) distribution, we modeled fluconazole concentration and area under the curve (AUC) relative to MIC to propose a rational fluconazole dosing strategy. METHODS: First, we conducted a systematic review using the MEDLINE database for reports of fluconazole MIC distribution against clinical Cryptococcus isolates. Second, we utilized fluconazole concentrations from 92 Ugandans who received fluconazole 800 mg/day coupled with fluconazole’s known pharmacokinetics to predict plasma fluconazole concentrations for doses ranging from 100 mg to 2000 mg via linear regression. Third, the fluconazole AUC above MIC ratio were calculated using Monte Carlo simulation and using the MIC distribution elucidated during the systemic review. RESULTS: We summarized 21 studies with 11,094 clinical Cryptococcus isolates. MICs were normally distributed with geometric mean of 3.4 mg/mL, median (MIC(50)) of 4 mg/mL, and 90th percentile (MIC(90)) of 16 mg/mL. The median MIC(50) trended upwards from 4 mg/mL in 2000–2012 to 8 mg/mL in 2014–2018. Predicted sub-therapeutic fluconazole concentrations (below MIC) would occur in 38% with 100 mg, 20% with 200 mg, and 8% with 400 mg. AUC/MIC ratio > 100 would occur in 53% for 400 mg, 74% for 800 mg, 84% for 1200 mg, and 88% for 1,600 mg. CONCLUSION: Currently recommended fluconazole doses may be inadequate for cryptococcosis. Further clinical studies are needed for rational fluconazole dose selection. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6809647/ http://dx.doi.org/10.1093/ofid/ofz360.1800 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Chesdachai, Supavit Rajasingham, Radha Nicol, Melanie R Meya, David Bongomin, Felix Abassi, Mahsa Skipper, Caleb Kwizera, Richard Rhein, Joshua Boulware, David 2120. Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model |
title | 2120. Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model |
title_full | 2120. Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model |
title_fullStr | 2120. Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model |
title_full_unstemmed | 2120. Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model |
title_short | 2120. Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model |
title_sort | 2120. minimum inhibitory concentration distribution of fluconazole against cryptococcus species and the fluconazole exposure prediction model |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809647/ http://dx.doi.org/10.1093/ofid/ofz360.1800 |
work_keys_str_mv | AT chesdachaisupavit 2120minimuminhibitoryconcentrationdistributionoffluconazoleagainstcryptococcusspeciesandthefluconazoleexposurepredictionmodel AT rajasinghamradha 2120minimuminhibitoryconcentrationdistributionoffluconazoleagainstcryptococcusspeciesandthefluconazoleexposurepredictionmodel AT nicolmelanier 2120minimuminhibitoryconcentrationdistributionoffluconazoleagainstcryptococcusspeciesandthefluconazoleexposurepredictionmodel AT meyadavid 2120minimuminhibitoryconcentrationdistributionoffluconazoleagainstcryptococcusspeciesandthefluconazoleexposurepredictionmodel AT bongominfelix 2120minimuminhibitoryconcentrationdistributionoffluconazoleagainstcryptococcusspeciesandthefluconazoleexposurepredictionmodel AT abassimahsa 2120minimuminhibitoryconcentrationdistributionoffluconazoleagainstcryptococcusspeciesandthefluconazoleexposurepredictionmodel AT skippercaleb 2120minimuminhibitoryconcentrationdistributionoffluconazoleagainstcryptococcusspeciesandthefluconazoleexposurepredictionmodel AT kwizerarichard 2120minimuminhibitoryconcentrationdistributionoffluconazoleagainstcryptococcusspeciesandthefluconazoleexposurepredictionmodel AT rheinjoshua 2120minimuminhibitoryconcentrationdistributionoffluconazoleagainstcryptococcusspeciesandthefluconazoleexposurepredictionmodel AT boulwaredavid 2120minimuminhibitoryconcentrationdistributionoffluconazoleagainstcryptococcusspeciesandthefluconazoleexposurepredictionmodel |